ERBB2 and carcinoma: When the HER2 amplification status between subtypes according to the WHO classification is evaluated in tubular adenocarcinomas, the frequency of amplification was found to be statistically significantly higher than poorly cohesive carcinoma, mucinous adenocarcinoma, and CWLS (P < .000).